It is called Kaftrio: this treatment, produced by the Vertex laboratory, is considered a revolution in the fight against cystic fibrosis. This disease, which attacks the respiratory and digestive systems, was previously often fatal for affected children and adolescents.
The hope of an “almost ordinary life”
This was announced by the Minister of Health, François Braun an interview with Sunday newspaperpublished on 17 December 2022, that the Kaftrio, authorized on the European Union market since August 2020, could now be prescribed to children with cystic fibrosis under the age of 12, but more than 6 years. According to the minister, the Kaftrio would have shown ” extraordinary results “and would allow a” almost ordinary life ».
The cure would even be able for some patients to transform the disease, of genetic origin, into a chronic and stabilized pathology. It would reduce, among other things, lung conditions, which are particularly debilitating. Access to the Kaftrio for children aged 6 to 11 is therefore includeda feeling of hope and great relief for the families of the sick.
The decree is ready and should be published in the coming days, announced the Minister of Health, François Braun
« The decree is ready and should be published in the coming days “, announced the Minister of Health, François Braun, who adds that the drug, delivered in the form of tablets for lifeshould be available” very quickly ” in the pharmacy, by hospital prescription.
More than 700 new beneficiaries
People with cystic fibrosis aged 12 and older and carrying a specific mutation have been able to benefit from Kaftrio since June 2021, in France. Expanding access to care will allow more than 700 children to benefit from it. 200 of them are already undergoing treatment, as part of Early Access.
The president of the “Vaincre Mucoviscidose” association, David Fiant, indicated on Saturday 17 December, on the website of Parisianthat nearly 5,000 people with the disease would have access to Kaftrio in the first quarter of 2023.
35% of patients are still waiting
However, Kaftrio, like any experimental treatment, not suitable for all patients. Thus, almost 35% of people with cystic fibrosis are still waiting for an innovation that allows them to live peacefully.
Your horoscope by email
Thanks for your registration.
The information concerning you is intended for sending your horoscope via newsletter. They are kept for a period of three years from the last contact. This information may be used for automated decision making to evaluate your personal preferences or interests. In accordance with the French law “Informatique et Libertés” n° 78-17 of 6 January 1978 and subsequent amendments and European Regulation 2016/679, you can request access to information concerning you, to have it rectified, modified or deleted, for object to their treatment by email to dpo@uni-medias.com or by post to the following address: Uni-médias, for the attention of the DPO, 22 rue Letellier – 75015 – Paris, or to request their portability, by writing by mail to the following address: Uni-médias, for the attention of the DPO, 22 rue Letellier – 75015 – Paris or by email to dpo@uni-medias.com. You can also define the conditions of use, storage and communication of your personal data in the event of death. For any request relating to your personal data, you can contact the data protection officer at the following email address: dpo@uni-medias.com, or file a complaint with the Commission Nationale Informatique et Libertés.
